{"id":"budesonide-hfa-pmdi","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nervousness"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Throat irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Budesonide is a selective glucocorticoid receptor agonist that decreases airway inflammation by inhibiting the release of inflammatory cytokines, chemokines, and adhesion molecules. The HFA (hydrofluoroalkane) pMDI formulation delivers the drug directly to the lungs via pressurized metered-dose inhaler, providing local anti-inflammatory effects with minimal systemic absorption.","oneSentence":"Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:18.570Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT06473779","phase":"PHASE3","title":"Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Severe Asthma","enrollment":326},{"nctId":"NCT02165046","phase":"PHASE1","title":"Bioavailability Study of SYN006, Pulmicort pMDI and Meptin Air in Healthy Adult.","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2012-02","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":24},{"nctId":"NCT01136655","phase":"PHASE2","title":"A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-09","conditions":"Asthma","enrollment":54},{"nctId":"NCT00667992","phase":"PHASE3","title":"Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Asthma","enrollment":99},{"nctId":"NCT00419952","phase":"PHASE3","title":"A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-02","conditions":"Asthma","enrollment":742},{"nctId":"NCT00419757","phase":"PHASE3","title":"An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Asthma","enrollment":558},{"nctId":"NCT00536913","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-09","conditions":"Asthma","enrollment":107},{"nctId":"NCT00651768","phase":"PHASE3","title":"Titratable Dosing in Moderate to Severe Asthmatics","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-08","conditions":"Asthma","enrollment":570},{"nctId":"NCT00646009","phase":"PHASE3","title":"Symbicort Onset of Action 2","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-03","conditions":"Asthma","enrollment":48},{"nctId":"NCT00449501","phase":"PHASE3","title":"A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-03","conditions":"Asthma","enrollment":134},{"nctId":"NCT00449527","phase":"PHASE3","title":"A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-03","conditions":"Asthma","enrollment":123},{"nctId":"NCT00975754","phase":"PHASE1","title":"Lung Deposition Via Different Inhalation Devices","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-09","conditions":"Healthy Volunteers","enrollment":16},{"nctId":"NCT00646620","phase":"PHASE3","title":"Symbicort Onset of Action 1","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-04","conditions":"Asthma","enrollment":48},{"nctId":"NCT00867737","phase":"PHASE4","title":"Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)","status":"UNKNOWN","sponsor":"Allergy and Asthma Center of El Paso","startDate":"2008-09","conditions":"Asthma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"LOBAR PNEUMONIA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Budesonide HFA pMDI","genericName":"Budesonide HFA pMDI","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Budesonide HFA pMDI is a small molecule that acts as a glucocorticoid receptor agonist, classified as an AGONIST. It is used to treat conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD), as indicated by studies on ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}